Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents.
about
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivityDesigned oligomers of cyanovirin-N show enhanced HIV neutralizationRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesEngineering antibody-like inhibitors to prevent and treat HIV-1 infection.Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogensA dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicityStabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchangeRational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.Phenotypic properties of transmitted founder HIV-1A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein.Antibody engineering for increased potency, breadth and half-life.Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.Enhanced HIV-1 neutralization by antibody heteroligationMonoclonal antibody-based candidate therapeutics against HIV type 1.Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination.Comparative analysis of anti-polyglutamine Fab crystals grown on Earth and in microgravity.Candidate antibody-based therapeutics against HIV-1.Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).Engineering broadly neutralizing antibodies for HIV prevention and therapy.A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells.Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins
P2860
Q27660384-6AB7026B-A644-49DB-857D-61BDFC7EC7A9Q27671182-01C05D8F-641E-4358-B27F-B30AA6442DEAQ28068946-14E96A32-1C40-489B-9399-9CD014A9729BQ30490945-0FEF9B45-A7A4-4431-95DD-0B7D8ED6BAE7Q33657941-ACBF8E27-6220-4249-B961-D20A5F565181Q33946209-DF1A6278-6535-41BE-8A7D-82FEC94E6B8CQ33969383-F9931448-334F-4B0C-BEEA-89E1A98A3704Q34055984-A15B5835-C04B-43A7-9612-F9BC408738CDQ34174815-D764687A-DF49-46E4-83F0-83211962A482Q34336058-D8707CCE-63C0-4AC8-AB03-B76C118A4E82Q35140318-FE8BAF53-58D4-449D-A5FD-7F43AA93C467Q35575206-43204E70-421D-4B3B-BD98-C8A9F49619C4Q35677620-F4520F1A-0298-4B89-997B-9F912E0A3501Q35735385-03A065C3-45D5-47EB-A96C-E08FBFF59279Q35904501-DE7C5FEC-D84A-444F-A6D7-E75916DE98A7Q36172480-FD288119-4D63-4521-B27C-AD4815BC94A0Q37316264-6C556A58-9EB7-420B-BB68-6EEA89EE4B03Q37998496-64BB3422-984E-40CE-A683-9CD580376EBEQ38206519-307BEE67-309E-4A39-B258-E64404DB3DDAQ38717198-3377D677-65E4-44FD-89BA-4DB10BD42709Q39048904-5E6F1B77-2847-4692-96BE-591D1164A4E0Q39261383-99B33CD9-98C9-4C73-BBBD-334F01C9CEF4Q58555325-6C7BA885-641B-4F79-B87D-F221EC863D97
P2860
Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@ast
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@en
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@nl
type
label
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@ast
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@en
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@nl
prefLabel
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@ast
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@en
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of CD4-CD4i antibod ...... munodeficiency virus reagents.
@en
P2093
Anthony P West
Christopher P Foglesong
Joshua S Klein
Priyanthi N P Gnanapragasam
Rachel P Galimidi
P2860
P304
P356
10.1128/JVI.01528-09
P577
2010-01-01T00:00:00Z